Luly Jay R. insider trades
Luly Jay R. has filed 25 Form 4s with the SEC that we hold, all for Enanta Pharmaceuticals INC (ENTA), as President and CEO, Director. Across all of them we count 1 purchase worth $256.1K and 10 sales worth $3.0M reported on Form 4. In the last 12 months: 0 purchases ($0) and 1 sale ($67.5K). The largest single trade was a sale of 15,649 shares of Enanta Pharmaceuticals INC worth $709.1K, dated 2023-03-13. The first filing on our record is dated 2021-09-17 and the latest 2026-02-13.
Enanta Pharmaceuticals INC (ENTA)
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2021-09-15 | S, sale reported on Form 4 | 4,516 | $266.7K | 2021-09-17 |
| 2022-12-16 | S, sale reported on Form 4 | 8,597 | $382.9K | 2022-12-16 |
| 2022-12-16 | S, sale reported on Form 4 | 7,800 | $340.0K | 2022-12-16 |
| 2022-12-16 | S, sale reported on Form 4 | 13,603 | $618.8K | 2022-12-16 |
| 2023-03-13 | S, sale reported on Form 4 | 15,649 | $709.1K | 2023-03-14 |
| 2023-03-13 | S, sale reported on Form 4 | 1,566 | $72.2K | 2023-03-14 |
| 2023-03-13 | S, sale reported on Form 4 | 10,697 | $479.3K | 2023-03-14 |
| 2023-12-05 | S, sale reported on Form 4 | 7,230 | $69.6K | 2023-12-06 |
| 2024-12-06 | S, sale reported on Form 4 | 5,142 | $41.4K | 2024-12-10 |
| 2025-02-12 | P, purchase reported on Form 4 | 45,000 | $256.1K | 2025-02-12 |
| 2025-12-05 | S, sale reported on Form 4 | 4,743 | $67.5K | 2025-12-05 |
Counted from the Form 4 filings this reporting owner (SEC CIK 1571211) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.
Source: U.S. Securities and Exchange Commission (EDGAR) and other official
government data · Updated 2026-10-12 ·
For informational purposes only, not investment advice.
Privacy · Terms